Randomised, double-blind, placebo-controlled trials of non-individualised homeopathic treatment: systematic review and meta-analysis

被引:82
|
作者
Mathie, Robert T. [1 ]
Ramparsad, Nitish [2 ]
Legg, Lynn A. [3 ]
Clausen, Juergen [4 ]
Moss, Sian [1 ]
Davidson, Jonathan R. T. [5 ]
Messow, Claudia-Martina [2 ]
McConnachie, Alex [2 ]
机构
[1] Homeopathy Res Inst, London, England
[2] Univ Glasgow, Inst Hlth & Wellbeing, Robertson Ctr Biostat, Glasgow, Lanark, Scotland
[3] Univ Strathclyde, Dept Biomed Engn, Glasgow, Lanark, Scotland
[4] Karl & Veronica Carstens Stiftung, Essen, Germany
[5] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA
关键词
Non-individualised homeopathy; Meta-analysis; Randomised controlled trials; Sensitivity analysis; Systematic review; PUBLICATION BIAS; EFFICACY; FILL; TRIM;
D O I
10.1186/s13643-017-0445-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: A rigorous systematic review and meta-analysis focused on randomised controlled trials (RCTs) of non-individualised homeopathic treatment has not previously been reported. We tested the null hypothesis that the main outcome of treatment using a non-individualised (standardised) homeopathic medicine is indistinguishable from that of placebo. An additional aim was to quantify any condition-specific effects of non-individualised homeopathic treatment. Methods: Literature search strategy, data extraction and statistical analysis all followed the methods described in a pre-published protocol. A trial comprised 'reliable evidence' if its risk of bias was low or it was unclear in one specified domain of assessment. 'Effect size' was reported as standardised mean difference (SMD), with arithmetic transformation for dichotomous data carried out as required; a negative SMD indicated an effect favouring homeopathy. Results: Forty-eight different clinical conditions were represented in 75 eligible RCTs. Forty-nine trials were classed as 'high risk of bias' and 23 as 'uncertain risk of bias'; the remaining three, clinically heterogeneous, trials displayed sufficiently low risk of bias to be designated reliable evidence. Fifty-four trials had extractable data: pooled SMD was -0.33 (95% confidence interval (CI) -0.44, -0.21), which was attenuated to -0.16 (95% CI -0.31, -0.02) after adjustment for publication bias. The three trials with reliable evidence yielded a non-significant pooled SMD: -0.18 (95% CI -0.46, 0.09). There was no single clinical condition for which meta-analysis included reliable evidence. Conclusions: The quality of the body of evidence is low. A meta-analysis of all extractable data leads to rejection of our null hypothesis, but analysis of a small sub-group of reliable evidence does not support that rejection. Reliable evidence is lacking in condition-specific meta-analyses, precluding relevant conclusions. Better designed and more rigorous RCTs are needed in order to develop an evidence base that can decisively provide reliable effect estimates of non-individualised homeopathic treatment.
引用
收藏
页数:28
相关论文
共 50 条
  • [21] Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials
    Zheng, W.
    Li, X-H.
    Yang, X-H.
    Cai, D-B.
    Ungvari, G. S.
    Ng, C. H.
    Wang, S-B.
    Wang, Y-Y.
    Ning, Y-P.
    Xiang, Y-T.
    PSYCHOLOGICAL MEDICINE, 2018, 48 (01) : 72 - 81
  • [22] Statins and risk of cancer: A meta-analysis of randomized, double-blind, placebo-controlled trials
    Kim, M. K.
    Myung, S. K.
    Tran, B. T.
    Park, B.
    INDIAN JOURNAL OF CANCER, 2017, 54 (02) : 470 - 477
  • [23] Adjunctive celecoxib for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials
    Zheng, Wei
    Cai, Dong-Bin
    Yang, Xin-Hu
    Ungvari, Gabor S.
    Ng, Chee H.
    Mueller, Norbert
    Ning, Yu-Ping
    Xiang, Yu-Tao
    JOURNAL OF PSYCHIATRIC RESEARCH, 2017, 92 : 139 - 146
  • [24] Adjunctive Fluvoxamine for Schizophrenia: A Meta-analysis of Randomized Double-Blind, Placebo-Controlled Trials
    Zheng, Wei
    Xiang, Ying-Qiang
    Cai, Dong-Bin
    Yang, Xin-Hu
    Zhang, Ling
    Lu, Xiao-Bing
    Tong, Yan-Ming
    Huang, Xiong
    Ungvari, Gabor S.
    Sim, Kang
    Ning, Yu-Ping
    Xiang, Yu-Tao
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2020, 40 (04) : 386 - 390
  • [25] Adjunctive Reboxetine for Schizophrenia: Meta-analysis of Randomized Double-blind, Placebo-controlled Trials
    Zheng, Wei
    Li, Xian-Bin
    Shi, Zhan-Ming
    Yang, Xin-Hu
    Cai, Dong-Bin
    Ng, Chee H.
    Ungvari, Gabor S.
    Liu, Wei-Jian
    Wu, Yu-Jie
    Wang, Yuan-Yuan
    Ning, Yu-Ping
    Xiang, Yu-Tao
    PHARMACOPSYCHIATRY, 2020, 53 (01) : 5 - 13
  • [26] Analgesic Efficacy of Melatonin: A Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials
    Oh, Si Nae
    Myung, Seung-Kwon
    Jho, Hyun Jung
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (05)
  • [27] Adjunctive azapirone for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials
    Zheng, Wei
    Li, Xiao-Hong
    Cai, Dong-Bin
    Yang, Xin-Hu
    Ungvari, Gabor S.
    Ng, Chee H.
    Ning, Yu-Ping
    Xiang, Yu-Tao
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2018, 28 (01) : 149 - 158
  • [28] Dietary supplements and prostate cancer: a systematic review of double-blind, placebo-controlled randomised clinical trials
    Posadzki, Paul
    Lee, Myeong Soo
    Onakpoya, Igho
    Lee, Hye Won
    Ko, Byong Seob
    Ernst, Edzard
    MATURITAS, 2013, 75 (02) : 125 - 130
  • [29] Dual orexin receptor antagonists for treatment of insomnia: A systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant
    Khazaie, Habibolah
    Sadeghi, Masoud
    Khazaie, Sepideh
    Hirshkowitz, Max
    Sharafkhaneh, Amir
    FRONTIERS IN PSYCHIATRY, 2022, 13
  • [30] A Systematic Review and Meta-analysis of Randomized, Double-Blind, Placebo-Controlled Trials of GABAB Receptor Agonists on Regulating Human Cough
    Wei, Weili
    ZhangTong, Yangzi
    Chen, Qiang
    Yu, Li
    Qiu, Zhongmin
    CHEST, 2016, 149 (04) : 549A - 549A